Proposed Data Collection Submitted for Public Comment and Recommendations, 79921-79922 [2024-22476]
Download as PDF
<![CDATA[
79921
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–24JB; Docket No. CDC–2024–
0075]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a proposed information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled National
Surveillance for C. auris Cases. The
purpose of this project is to collect
minimal pertinent information about C.
auris cases based on the Council of State
and Territorial Epidemiologists (CSTE)
case definition.
DATES: CDC must receive written
comments on or before December 2,
2024.
SUMMARY:
You may submit comments,
identified by Docket No. CDC–2024–
0075 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
ADDRESSES:
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
www.regulations.gov. Please note:
Submit all comments through the
Federal eRulemaking portal
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
Proposed Project
National Surveillance for C. auris
Cases—New—National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Candida auris (C. auris) is an
emerging healthcare-associated fungal
pathogen associated with high mortality
and antifungal resistance. The incidence
of C. auris cases has continued to
increase globally and in the United
States. Most cases are the result of
healthcare transmission and have
mortality estimates between 30–60%. C.
auris can asymptomatically colonize the
skin and other body sites, which
contributes to potential spread and
increases patients’ risk of clinical
infections. The persistence of C. auris
on the skin has been linked to an
increased risk in the development of C.
auris-related bloodstream infections in
adults and pediatric cases. These
clinical infections can be severe and
invasive and are associated with high
mortality.
The goal of the National Surveillance
for C. auris Cases is to monitor burden
to guide public health action and
ultimately prevent morbidity and
mortality from C. auris. In coordination
with the states/jurisdictions that submit
data, CDC plans to share, present, and
publish findings to the general public
on the burden of C. auris in the United
States. CDC requests OMB approval of
an estimated 1,303 annual burden
hours. There is no cost to respondents
other than their time.
khammond on DSKJM1Z7X2PROD with NOTICES
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Average
burden per
response
(in hours)
Number of
responses per
respondent
Total burden
(in hours)
Type of respondents
Form name
States/Jurisdictions ...........................
MDB Candida auris ..........................
46
340
5/60
1,303
Total ...........................................
...........................................................
........................
........................
........................
1,303
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
E:\FR\FM\01OCN1.SGM
01OCN1
79922
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Public Health Ethics and
Regulations, Office of Science, Centers for
Disease Control and Prevention.
[FR Doc. 2024–22476 Filed 9–30–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60Day–24–1046; Docket No. CDC–2024–
0074]
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other federal
agencies the opportunity to comment on
a continuing information collection, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on a proposed information
collection project titled National Breast
and Cervical Cancer Early Detection
Program (NBCCEDP) Monitoring
Activities. This data collection is
designed to systematically collect
information about implementation,
including delivery of screening and
follow-up clinical services, and
outcomes of the National Breast and
Cervical Cancer Early Detection Program
(NBCCEDP).
DATES: CDC must receive written
comments on or before December 2,
2024.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2024–
0074 by either of the following methods:
• Federal eRulemaking Portal:
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS H21–8, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
www.regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
(www.regulations.gov) or by U.S. mail to
the address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS
H21–8, Atlanta, Georgia 30329;
Telephone: 404–639–7570; Email: omb@
cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected;
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses; and
5. Assess information collection costs.
Proposed Project
National Breast and Cervical Cancer
Early Detection Program (NBCCEDP)
Monitoring Activities (OMB Control No.
0920–1046, Exp. 03/31/2025)—
Revision—National Center for Chronic
Disease Prevention and Health
Promotion (NCCDPHP), Centers for
Disease Control and Prevention (CDC).
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Background and Brief Description
CDC is requesting a Revision of the
information collection titled National
Breast and Cervical Cancer Early
Detection Program (NBCCEDP)
Monitoring Activities (OMB Control No.
0920–1046). The information collection
consists of an annual NBCCEDP survey,
baseline and annual clinic-level data
collection, a quarterly program update
(QPU) tool, a service delivery projection
worksheet, and minimum data elements
(MDEs). CDC proposes revisions to the
Annual NBCCEDP Survey, clinic-level
data collection tool and QPU, and
continued use of the service delivery
projection worksheet and MDEs with no
changes. The number of respondents
will increase from 70 to 71 and the total
estimated annualized burden will
decrease from 1,220 hours to 1,162
hours.
Breast and cervical cancers are
prevalent among U.S. women. In 2021,
the U.S. experienced 272,454 new cases
and 42,211 deaths as a result of breast
cancer, as well as 12,536 new cases and
4,051 deaths as a result of cervical
cancer. Evidence shows that deaths
from both breast and cervical cancers
can be avoided by increasing screening
services—mammography, pap, and
human papillomavirus (HPV) tests—
among women. However, in 2021,
approximately one quarter of adults
were not up to date with breast and/or
cervical cancer screening, and screening
was underutilized among women who
are under- or uninsured, have no regular
source of healthcare, or who recently
immigrated to the U.S. As a
longstanding priority within chronic
disease prevention, CDC focuses on
increasing access to these cancer
screenings, particularly among women
who may be at increased risk.
To improve access to cancer
screening, Congress passed the Breast
and Cervical Cancer Mortality
Prevention Act of 1990 (Pub. L. 106–
354), which directed CDC to create the
National Breast and Cervical Cancer
Early Detection Program (NBCCEDP).
The NBCCEDP currently provides
funding to 71 recipients under ‘‘Cancer
Prevention and Control Programs for
State, Territorial, and Tribal
Organizations (DP22–2202).’’ NBCCEDP
awardees include states or their bona
fide agents; U.S. territories; and tribes or
tribal organizations. The purpose of
NBCCEDP is to increase breast and
cervical cancer screening rates among
women residing within defined
geographical locations (as determined
by the funded program) who are at or
below 250% of the federal poverty level;
aged 50–75 years for breast cancer
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Pages 79921-79922]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22476]
[[Page 79921]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-24-24JB; Docket No. CDC-2024-0075]
Proposed Data Collection Submitted for Public Comment and
Recommendations
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice with comment period.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), as part
of its continuing effort to reduce public burden and maximize the
utility of government information, invites the general public and other
federal agencies the opportunity to comment on a proposed information
collection, as required by the Paperwork Reduction Act of 1995. This
notice invites comment on a proposed information collection project
titled National Surveillance for C. auris Cases. The purpose of this
project is to collect minimal pertinent information about C. auris
cases based on the Council of State and Territorial Epidemiologists
(CSTE) case definition.
DATES: CDC must receive written comments on or before December 2, 2024.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2024-
0075 by either of the following methods:
Federal eRulemaking Portal: www.regulations.gov. Follow
the instructions for submitting comments.
Mail: Jeffrey M. Zirger, Information Collection Review
Office, Centers for Disease Control and Prevention, 1600 Clifton Road
NE, MS H21-8, Atlanta, Georgia 30329.
Instructions: All submissions received must include the agency name
and Docket Number. CDC will post, without change, all relevant comments
to www.regulations.gov. Please note: Submit all comments through the
Federal eRulemaking portal (www.regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To request more information on the
proposed project or to obtain a copy of the information collection plan
and instruments, contact Jeffrey M. Zirger, Information Collection
Review Office, Centers for Disease Control and Prevention, 1600 Clifton
Road NE, MS H21-8, Atlanta, Georgia 30329; Telephone: 404-639-7570;
Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the Paperwork Reduction Act of 1995
(PRA) (44 U.S.C. 3501-3520), federal agencies must obtain approval from
the Office of Management and Budget (OMB) for each collection of
information they conduct or sponsor. In addition, the PRA also requires
federal agencies to provide a 60-day notice in the Federal Register
concerning each proposed collection of information, including each new
proposed collection, each proposed extension of existing collection of
information, and each reinstatement of previously approved information
collection before submitting the collection to the OMB for approval. To
comply with this requirement, we are publishing this notice of a
proposed data collection as described below.
The OMB is particularly interested in comments that will help:
1. Evaluate whether the proposed collection of information is
necessary for the proper performance of the functions of the agency,
including whether the information will have practical utility;
2. Evaluate the accuracy of the agency's estimate of the burden of
the proposed collection of information, including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and clarity of the information to
be collected;
4. Minimize the burden of the collection of information on those
who are to respond, including through the use of appropriate automated,
electronic, mechanical, or other technological collection techniques or
other forms of information technology, e.g., permitting electronic
submissions of responses; and
5. Assess information collection costs.
Proposed Project
National Surveillance for C. auris Cases--New--National Center for
Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Candida auris (C. auris) is an emerging healthcare-associated
fungal pathogen associated with high mortality and antifungal
resistance. The incidence of C. auris cases has continued to increase
globally and in the United States. Most cases are the result of
healthcare transmission and have mortality estimates between 30-60%. C.
auris can asymptomatically colonize the skin and other body sites,
which contributes to potential spread and increases patients' risk of
clinical infections. The persistence of C. auris on the skin has been
linked to an increased risk in the development of C. auris-related
bloodstream infections in adults and pediatric cases. These clinical
infections can be severe and invasive and are associated with high
mortality.
The goal of the National Surveillance for C. auris Cases is to
monitor burden to guide public health action and ultimately prevent
morbidity and mortality from C. auris. In coordination with the states/
jurisdictions that submit data, CDC plans to share, present, and
publish findings to the general public on the burden of C. auris in the
United States. CDC requests OMB approval of an estimated 1,303 annual
burden hours. There is no cost to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response Total burden
respondents respondent (in hours) (in hours)
----------------------------------------------------------------------------------------------------------------
States/Jurisdictions.......... MDB Candida 46 340 5/60 1,303
auris.
---------------------------------------------------------------------------------
Total..................... ................ .............. .............. .............. 1,303
----------------------------------------------------------------------------------------------------------------
[[Page 79922]]
Jeffrey M. Zirger,
Lead, Information Collection Review Office, Office of Public Health
Ethics and Regulations, Office of Science, Centers for Disease Control
and Prevention.
[FR Doc. 2024-22476 Filed 9-30-24; 8:45 am]
BILLING CODE 4163-18-P
